Two patents for cancer research involving Medipol researchers
A scientific study involving Prof. Mustafa Güzel, a faculty member at Istanbul Medipol University School of Pharmacy, and researcher Betül Yaşin investigated newly developed molecules exhibiting anticancer activity against breast, prostate, and lung cancer cells. The drug candidate molecules developed through the collaborative research with Zonguldak Bülent Ecevit University received a national patent, while the European patent application was also deemed eligible for registration.
Istanbul Medipol University contributed to a significant scientific study aimed at developing new drug candidates for cancer treatment. Conducted in collaboration with Zonguldak Bülent Ecevit University (BEUN), the research examined the effects of newly synthesized molecules on breast, prostate, and lung cancer cells. Laboratory experiments revealed that the molecules exhibited anticancer activity against cells representing all three types of cancer, producing promising findings for the development of potential new treatment options.
ANTICANCER ACTIVITIES INVESTIGATED AT MEDIPOL
Supported under BEUN's Scientific Research Projects program, the study was conducted in two stages. In the first stage, the synthesis of new molecules was completed by Prof. Zuhal Gerçek, a faculty member in the Department of Chemistry at BEUN's School of Science. In the second stage, Prof. Mustafa Güzel, a faculty member at Istanbul Medipol University School of Pharmacy, and researcher Betül Yaşin investigated the anticancer activities of the molecules through in vitro and cell culture experiments. These analyses demonstrated the biological effects of the molecules on breast, prostate, and lung cancer cells.
EUROPEAN PATENT APPLICATION APPROVED
The invention titled “Novel Arylidene Barbiturate Derivative Molecules as Potential Drug Candidates for Cancer Treatment,” developed as part of the research, was registered by the Turkish Patent and Trademark Office on July 22, 2024. Covering four different chemical compounds and their various chemical forms, the invention's European patent application was also deemed eligible for registration. This marked an important milestone in securing international intellectual property protection for the research findings.
SCIENTIFIC FOUNDATION FOR NEW DRUG DEVELOPMENT
Conducted through interuniversity collaboration, the research contributed to Türkiye's domestic drug development efforts while establishing a scientific foundation for investigating new molecules with potential applications in cancer treatment. However, further efficacy and safety studies, along with clinical trials, are required before the laboratory findings can be translated into clinical applications.
Last Update : 09/11/2026 - 11:00
